Improved bleeding profile and tolerability of tibolone versus transdermal E₂/NETA treatment in postmenopausal women with female sexual dysfunction

References

• Nappi R E, Wawra K, Schmitt S. Hypoactive sexual desire disorder in postmenopausal women. Gynecol Endocrinol 2006; 22: 318–323
   PubMed Web of Science ®Google Scholar
• Kovalevsky G. Female sexual dysfunction and use of hormone therapy in postmenopausal women. Semin Reprod Med 2005; 23: 180–187
   PubMed Web of Science ®Google Scholar
• Nathorst-Boos J, Hammar M. Effect on sexual life – a comparison between tibolone and a continuous estradiol–norethisterone acetate regimen. Maturitas 1997; 26: 15–20
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Vicente J, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000; 34: 161–168
   PubMed Web of Science ®Google Scholar
• Kloosterboer H J. Tissue selectivity: the mechanism of action of tibolone. Maturitas 2004; 48(Suppl 1)S30–S40
   PubMedGoogle Scholar
• De Gooyer M E, Deckers G H, Schoonen W GEJ, Verheul H AM, Kloosterboer H J. Receptor profiling and endocrine interactions of tibolone. Steroids 2003; 68: 21–30
   PubMed Web of Science ®Google Scholar
• Dören M, Rübig A, Coelingh Bennink H JT, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001; 75: 554–559
   PubMed Web of Science ®Google Scholar
• Langer R D, Landgren B M, Rymer J, Helmond F A. for the OPAL Investigators. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006; 195: 1320–1327
   PubMed Web of Science ®Google Scholar
• Huber J, Palacios S, Berglund L, et al. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002; 109: 886–893
   Google Scholar
• Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904–911
   PubMedGoogle Scholar
• Dören M, Rübig A, Coelingh Bennink H JT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999; 6: 299–306
   PubMed Web of Science ®Google Scholar
• Gooyer de M E, Overklift Vaupel Kleyn G T, Smits K C, Ederveen A GH, Verheul H AM, Kloosterboer H J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001; 183: 55–62
   PubMed Web of Science ®Google Scholar
• Kloosterboer H J. Tissue-selective effects of tibolone on the breast. Maturitas 2004; 49: S5–15
   PubMed Web of Science ®Google Scholar
• Lundström E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717–722
   PubMed Web of Science ®Google Scholar
• Lethaby A, Suckling J, Barlow D, Farquhar C M, Jepson R G, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3: CD000402
   PubMedGoogle Scholar
• Cheang A, Sitruk-Ware R, Utian W H. A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf 1993; 9: 365–379
   PubMed Web of Science ®Google Scholar
• Roy S, Boostanfar R, Saadet P, Poysky J. Serum endocrine markers and psychosexual mood in postmenopausal women: the difference between transdermal and oral HRT. Climacteric 2002; 5(Suppl 1)198
   Google Scholar
• Rogers R G, Simon J A, Ragavan V V. Combipatch® significantly improves Women's Sexual Quality of Life compared to PremproTM in a randomized trial. Poster presented at the 10th World Congress on the Menopause, BerlinGermany, June, 2002
   Google Scholar
• Nijland E A, Weijmar Schultz W C, Nathorst-Böös J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized, active-controlled trial. J Sex Med 2008; 5: 646–656
   PubMed Web of Science ®Google Scholar
• Archer D F, Furst K, Tipping D, Dain M P, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94: 498–503
   PubMed Web of Science ®Google Scholar
• Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Climacteric 2006; 9: 368–379
   PubMed Web of Science ®Google Scholar
• Hammar M, van de Weijer P, Franke H, Pornel B, von Mauw E, Nijland E. Tibolone and low dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. Br J Obstet Gynaecol 2007; 114: 1522–1529
   Google Scholar
• Archer D F, Navarro F J, Leslie S, Mirkin S. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone and 17β-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells. Fertil Steril 2004; 81: 165–170
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Schneider H P, Panay N, Nijland E A. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006; 22: 369–375
   PubMed Web of Science ®Google Scholar
• Harvey J, Scheurer C, Kawakami F T, Quebe-Fehling E, de Palacios P I, Ragavan V V. Hormone replacement therapy and breast density changes. Climacteric 2005; 8: 185–192
   PubMed Web of Science ®Google Scholar
• Hofling M, Carlström K, Svane G, Azavedo E, Kloosterboer H, Von Schoultz B. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels – an association with mammographic density. Gynecol Endocrinol 2005; 20: 110–115
   PubMed Web of Science ®Google Scholar